Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$37.1M+10.0%$25.71M+147%-$12.76M+81.9%-$41.23M+69.7%
$25.21M+96.9%$18.14M+50.0%$15.79M+40.5%$14.02M+35.5%$12.8M+29.6%
$16.15M+40.5%$11.46M+24.4%$11.26M+40.4%$10.65M+7.4%$11.49M+17.8%
-$40.37M+4.3%$60.68M+270%-$42.19M+64.5%
$21.55M-47.8%$86.59M+87.7%$4.85M-83.0%$41.29M-60.6%
$4.2M+13.1%-$65.34M-142,141%$1.48M+88.6%$3.72M+808%
-$14.67M-536%$35.78M+769%$13.26M+221%$3.36M+123%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Travere Therapeutics, Inc. generate?
Travere Therapeutics, Inc. (TVTX) generated -$57.6M in operating cash flow over the trailing twelve months.
Where does Travere Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.